Essential Access Health — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$70,885	19
2024	Research	$226,149	35
2023	Research	$426,585	52
2022	Research	$134,398	17
2021	Research	$176,917	62
2020	Research	$241,148	53
2019	Research	$505,383	57

Breakdown

Who paid Research payments · program years 2019–2025

Sebela Pharmaceuticals Inc. $798,394 119 payments
Mylan Inc. $474,709 67 payments
Organon LLC $322,659 80 payments
Sebela Women's Health Inc. $117,329 22 payments
Mylan Technologies Inc. $41,759 4 payments
Merck Sharp & Dohme Corporation $26,614 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $790,272 83 payments
Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $474,709 67 payments
Efficacy and Safety of Nexplanon 36 to 60 Months Post Insertion $131,580 17 payments
A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger $71,203 51 payments
Evaluation of the Effectiveness, Safety and Tolerability of LevoCept Levonorgestrel-Releasing Intrauterine System for Long-Acting Reversible Contraception $59,499 27 payments
8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B $53,818 1 payment
Evaluation of the Effectiveness, Safety and Tolerability of Levocept (Levonorgestrel-Releasing Intrauterine System) for Long-Acting Reversible Contraception $45,130 25 payments
Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $41,759 4 payments
8415-060 $21,116 2 payments
Evaluation of the Effectiveness, Feasibility, Safety and Tolerability of the ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception $20,822 6 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $322,659 80 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.